Elsa R. and Walter C. Chidester Professor of Surgery
Stanford University
Associate Dean for Market Development and Outreach
Stanford University Medical Center
Stanford, California
Session Moderator
SESSION 5: NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY, DETECTION, TREATMENT AND EVAR
Presenter
SESSION 5: NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY, DETECTION, TREATMENT AND EVAR
Session Moderator
SESSION 43: NEW DEVELOPMENTS IN AAA BEHAVIOR, TREATMENT AND STANDARD INFRARENAL EVAR: THE INFLUENCE OF DIABETES, BLOOD PRESSURE, AGE, ETC. ON AAA GROWTH; IMPROVED ULTRASOUND SURVEILLANCE, LOCAL ANESTHESIA FOR EVAR, 3D CTA ANALYSIS, CONSEQUENCES OF AAAS LOST TO FOLLOW-UP AND ALL AAAS ARE NOT TIME BOMBS WAITING TO EXPLODE
Presenter
SESSION 38: UPDATES AND ISSUES IMPORTANT TO ALL VASCULAR SURGEONS AND SPECIALISTS: FUTURE REIMBURSEMENT; IMPROVING VASCULAR CARE QUALITY; FIXING FALSE TESTIMONY; FLAWED PEER REVIEW; FDA IMPROVEMENTS; LEARNING HEALTH SYSTEMS
Presenter
SESSION 43: NEW DEVELOPMENTS IN AAA BEHAVIOR, TREATMENT AND STANDARD INFRARENAL EVAR: THE INFLUENCE OF DIABETES, BLOOD PRESSURE, AGE, ETC. ON AAA GROWTH; IMPROVED ULTRASOUND SURVEILLANCE, LOCAL ANESTHESIA FOR EVAR, 3D CTA ANALYSIS, CONSEQUENCES OF AAAS LOST TO FOLLOW-UP AND ALL AAAS ARE NOT TIME BOMBS WAITING TO EXPLODE
SESSION 5: NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY, DETECTION, TREATMENT AND EVAR
Presenter
SESSION 5: NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY, DETECTION, TREATMENT AND EVAR
Update On Medical Treatment Trials To Slow AAA Growth: What Treatments Or Drugs Show Promise And Why: What About Metformin And The MAAAGI And MAT Trials
1:24 PM - 1:29 PM
Session Moderator
SESSION 43: NEW DEVELOPMENTS IN AAA BEHAVIOR, TREATMENT AND STANDARD INFRARENAL EVAR: THE INFLUENCE OF DIABETES, BLOOD PRESSURE, AGE, ETC. ON AAA GROWTH; IMPROVED ULTRASOUND SURVEILLANCE, LOCAL ANESTHESIA FOR EVAR, 3D CTA ANALYSIS, CONSEQUENCES OF AAAS LOST TO FOLLOW-UP AND ALL AAAS ARE NOT TIME BOMBS WAITING TO EXPLODE
Presenter
SESSION 38: UPDATES AND ISSUES IMPORTANT TO ALL VASCULAR SURGEONS AND SPECIALISTS: FUTURE REIMBURSEMENT; IMPROVING VASCULAR CARE QUALITY; FIXING FALSE TESTIMONY; FLAWED PEER REVIEW; FDA IMPROVEMENTS; LEARNING HEALTH SYSTEMS
Leveraging The Vascular Quality Initiative To Reduce Length Of Stay Following EVAR And CEA
5:16 PM - 5:21 PM
Presenter
SESSION 43: NEW DEVELOPMENTS IN AAA BEHAVIOR, TREATMENT AND STANDARD INFRARENAL EVAR: THE INFLUENCE OF DIABETES, BLOOD PRESSURE, AGE, ETC. ON AAA GROWTH; IMPROVED ULTRASOUND SURVEILLANCE, LOCAL ANESTHESIA FOR EVAR, 3D CTA ANALYSIS, CONSEQUENCES OF AAAS LOST TO FOLLOW-UP AND ALL AAAS ARE NOT TIME BOMBS WAITING TO EXPLODE
How Does Patient Age At Endograft Implantation Influence The Durability Of EVAR Success: How Should This Guide The Choice Of Endo vs. Open Repair
1:12 PM - 1:17 PM